آزمایش ناموفق Novartis برای داروی کلسترول منجر به فروش گسترده بیوفارما می شود

Novartis’s failed trial for cholesterol drug leads to broad biopharma selloff

Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.